Detecting bioactive amyloid β peptide species in Alzheimer's disease

Journal of Neurochemistry

Volumn 91, Issue 3, 2004, Pages 648-656

  Liu, Yuanbin ^a   Dargusch, Richard ^a   Banh, Cindy ^a   Miller, Carol A ^b   Schubert, David ^a  

^a SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

3 (4, 5 dimethylthiazol 2 yl) 2; 5 diphenyltetrazolium bromide; Alzheimer's disease; Amyloid peptide; Amyloid fibrillogenesis; Bioactive amyloid species; Drug screening

Indexed keywords

AMYLOID BETA PROTEIN; CONGO RED; DEUTEROPORPHYRIN IX; IRON DEUTEROPORPHYRIN IX 2,4 BISETHYLENE GLYCOL; THIOFLAVINE; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CADAVER; CELL ASSAY; CORRELATION ANALYSIS; FEMALE; GLIA; HUMAN; HUMAN TISSUE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; RAT; SAMPLE; TRANSGENIC MOUSE;

AGE FACTORS; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID; AMYLOID BETA-PROTEIN; ANIMALS; ASTROCYTES; BRAIN CHEMISTRY; CELLS, CULTURED; DEUTEROPORPHYRINS; DISEASE MODELS, ANIMAL; EXOCYTOSIS; FEMALE; FORMAZANS; FRONTAL LOBE; HUMANS; MALE; MICE; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; RATS; RATS, SPRAGUE-DAWLEY; SENSITIVITY AND SPECIFICITY; STEM CELLS; TETRAZOLIUM SALTS;

ANIMALIA; MUS MUSCULUS;

EID: 7244225197     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2004.02751.x     Document Type: Article

References (31)

1. Berr C., Hauw J. J., Delaere P., Duyckaerts C. and Amouyel P. (1994) Apolipoprotein E allele epsilon 4 is linked to increased deposition of the amyloid beta-peptide (A-beta) in cases with or without Alzheimer's disease. Neurosci. Lett. 178, 221-224.
2. Borchelt D. R., Ratovitski T., van Lare J., Lee M. K., Gonzales V., Jenkins N. A., Copeland N. G., Price D. L. and Sisodia S. S. (1997) Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 19, 939-945.
3. Braak H. and Braak E. (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239-259.
4. Caughey B. and Lansbury P. T., Jr (2003) Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu. Rev. Neurosci. 26, 267-298.
5. Caughey W. S., Raymond L. D., Horiuchi M. and Caughey B. (1998) Inhibition of protease-resistant prion protein formation by porphyrins and phthalocyanines. Proc. Natl Acad. Sci. USA 95, 12117-12122.
6. Choo-Smith L. P., Garzon-Rodriguez W., Glabe C. G. and Surewicz W. K. (1997) Acceleration of amyloid fibril formation by specific binding of Abeta-(1-40) peptide to ganglioside-containing membrane vesicles. J. Biol. Chem. 272, 22 987-22 990.
7. Crystal H., Dickson D., Fuld P., Masur D., Scott R., Mehler M., Masdeu J., Kawas C., Aronson M. and Wolfson, L. (1988) Clinico-pathologic studies in dementia: nondemented subjects with pathologically confirmed Alzheimer's disease. Neurology 38, 1682-1687.
8. Davis J. N., 2nd and Chisholm J. C. (1997) The 'amyloid hypothesis' of AD: decoy or real McCoy? Trends Neurosci. 20, 558-559.
9. Delaere P., Duyckaerts C., Masters C., Beyreuther K., Piette F. and Hauw J. J. (1990) Large amounts of neocortical beta A4 deposits without neuritic plaques nor tangles in a psychometrically assessed, non-demented person. Neurosci. Lett. 116, 87-93.
10. Delaere P., He Y., Fayet G., Duyckaerts C. and Hauw J. J. (1993) Beta A4 deposits are constant in the brain of the oldest old: an immunocytochemical study of 20 French centenarians. Neurobiol. Aging 14, 191-194.
11. Dickson D. W., Crystal H. A., Mattiace L. A., Masur D. M., Blau A. D., Davies P., Yen S. H. and Aronson M. K. (1992) Identification of normal and pathological aging in prospectively studied nondemented elderly humans. Neurobiol. Aging 13, 179-189.
12. Findeis M. A. (2000) Approaches to discovery and characterization of inhibitors of amyloid β-peptide polymerization. Biochim. Biophys. Acta 1502, 76-84.
13. Hardy J. and Selkoe D. J. (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356.
14. Harper J. D. and Lansbury P. T., Jr (1997) Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu. Rev. Biochem. 66, 385-407.
15. Holcomb L., Gordon M. N., McGowan E. et al. (1998) Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nature Med. 4, 97-100.
16. Hu J., Akama K. T., Krafft G. A., Chromy B. A. and Van Eldik L. J. (1998) Amyloid-beta peptide activates cultured astrocytes: morphological alterations, cytokine induction and nitric oxide release. Brain Res. 785, 195-206.
17. Jankowsky J. L., Slunt H. H., Ratovitski T., Jenkins N. A., Copland N. G. and Borchelt D. R. (2001) Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol. Eng. 17, 157-165.
18. Klein W. L., Krafft G. A. and Finch C. E. (2001) Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum? Trends Neurosci. 24, 219-224.
19. Levison S. W. and McCarthy K. D. (1991) Astroglia in culture, in Culturing Nerve Cells (Banker, G. and Goslin, K., eds), pp. 309-336. MIT Press, Cambridge, MA.
20. Lewis J., Dickson D. W., Lin W. L. et al. (2001) Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293, 1487-1491.
21. Liu Y. (1999) Understanding the biological activity of amyloid proteins in vitro: from inhibited cellular MTT reduction to altered cellular cholesterol homeostasis. Prog. Neuro-Psychopharmacol. Psychiat. 23, 377-395.
22. Liu Y. and Piasecki D. (2001) A cell-based method for the detection of nanomolar concentrations of bioactive amyloid. Anal. Biochem. 289, 130-136.
23. Liu Y. and Schubert D. (1997) Cytotoxic amyloid peptides inhibit cellular MTT reduction by enhancing MTT formazan exocytosis. J. Neurochem. 69, 2285-2293.
24. Liu Y. and Schubert D. (1998) Steroid hormones block amyloid fibril-induced MTT formazan exocytosis: relationship to neurotoxicity. J. Neurochem. 71, 2322-2329.
25. Liu Y., Peterson D., Kimura H. and Schubert D. (1997) The mechanism of cellular MTT reduction. J. Neurochem. 69, 581-593.
26. Liu Y., Peterson D. and Schubert D. (1998) Amyloid β peptide alters intracellular vesicle trafficking and cholesterol homeostasis. Proc. Natl Acad. Sci. USA 95, 13 266-13 271.
27. Lorenzo A. and Yankner B. A. (1994) β-Amyloid neurotoxicity requires fibril formation and is inhibited by Congo red. Proc. Natl Acad. Sci. USA 91, 12 243-12 247.
28. McLaurin J., Franklin T., Zhang X., Deng J. and Fraser P. E. (1999) Interactions of Alzheimer amyloid-beta peptides with glycosaminoglycans effects on fibril nucleation and growth. Eur. J. Biochem. 266, 1101-1110.
29. Price D. L. and Sisodia S. S. (1998) Mutant genes in familial Alzheimer's disease and transgenic models. Annu. Rev. Neurosci. 21, 479-505.
30. Schubert D., Heinemann S., Carlisle W., Tarika H., Kimes B., Steinbach J. H., Culp W. and Brandt B. L. (1974) Clonal cell lines from the rat central nervous system. Nature 249, 224-227.
31. Wood S. J., Maleeff B., Hart T. and Wetzel R. (1996) Physical, morphological and functional differences between pH 5.8 and 7.4 aggregates of the Alzheimer's amyloid peptide Aβ. J. Mol. Biol. 256, 870-877.